The company said, “With the Chief Executive Officer and Chief Financial Officer transition, Maravai is withdrawing and suspending revenue guidance for 2025. The new leadership team is in the midst of a comprehensive business review and forecasting process and will look to reinstate guidance once that process is complete.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences Announces Major Organizational Restructuring
- Maravai Lifesciences Holdings, Inc. (MRVI) Q2 Earnings Cheat Sheet
- Strategic Leadership Changes and Financial Discipline Drive Buy Rating for Maravai Lifesciences Holdings
- Maravai Lifesciences Appoints New CFO Rajesh Asarpota
- Maravai Lifesciences CFO Kevin Herde to switch roles, Rajesh Asarpota to succeed